DNA Sequence Variability in Isolates Recovered from Patients with Postvaccination Rash or Herpes Zoster Caused by Oka Varicella Vaccine
1National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; 2Section of Pediatric Infectious Diseases, Department of Pediatrics, University of Colorado School of Medicine, Denver
Little is known about the pathogenic potential of individual strains in the varicella vaccine. We analyzed genomic variation among specimens obtained from vaccine recipients with postvaccination rash or herpes zoster (HZ), focusing on polymorphisms between live attenuated varicella vaccine virus and wild‐type varicella‐zoster virus. Eleven of 18 postvaccination HZ specimens contained >1 strain, and 7 of 18 appeared to be clonal. All 21 postvaccination rash specimens contained mixtures of vaccine strains. Four single‐nucleotide polymorphisms (SNPs) consistently occurred in every isolate; all were polymorphisms in open‐reading frame (ORF) 62, and 2 confer amino acid substitutions in the immediate‐early protein 62. Four wild‐type SNPs occurred in every isolate: one each occurred in ORF 10, ORF 21, ORF 62, and a noncoding region upstream of ORF 64. The frequencies of the remaining wild‐type SNPs were variable, with the SNPs uniformly expressed (even in mixtures) in 20.5%–97.4% of isolates (mean frequency, 67.7%). No 2 clinical isolates had identical SNP profiles; as such, vaccine latency usually involves >1 strain.
Received 5 May 2006; accepted 9 August 2006; electronically published 10 January 2007.
Cited by
Online publication date: 1-Aug-2009.
CrossRef
Online publication date: 15-Nov-2008.
Online publication date: 1-Mar-2008.
Online publication date: 1-Mar-2008.
Online publication date: 1-Mar-2008.
Online publication date: 1-Oct-2007.
CrossRef
Online publication date: 1-Sep-2007.
Online publication date: 1-Sep-2007.
-
Potential conflicts of interest: none reported.
Presented in entirety: 30th International Herpesvirus Workshop, Turku, Finland, 30 July through 4 August 2005 (abstract 4.17).
Financial support: National Vaccine Program Office Unmet Needs (grant N25 in 2003); core programmatic funds allocated to the Centers for Disease Control and Prevention.
All authors contributed equally to this work. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the funding agency.





